Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR®, with Product Development Roadmap for the Development of Antibody Drug Conjugates

~ Lantern is expanding RADR®’s product roadmap to enhance the development of novel and effective Antibody Drug Conjugates (ADCs) for the targeted delivery of potent anti-cancer small molecules to cancer cells. ~ RADR®’s AI and ML drug development modules have the potential to assist in advancing ADC drug candidates from the discovery phase to first-in-human clinical trials in approximately 2 years or less. ~ Lantern anticipates this expansion will significantly add to RADR®’s 25+ billion oncology focused data points and library of over 200+ algorithms. ~ The global ADC market is over $4.0 billion and is projected to reach $14.0 billion by 2027.

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here